Moderate To Severe Rheumatoid Arthritis With Methotrexate Inadequacy Therapeutics
1. Xeljanz patent expiration
Treatment: Treatment of adult patients with moderately to severely active ulcerative colitis (uc); Treatment of rheumatoid arthritis
XELJANZ's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7301023 | PF PRISM CV | Chiral salt resolution |
Dec, 2020
(5 years ago) | |
| US7265221 | PF PRISM CV | Pyrrolo[2,3-d]pyrimidine compounds |
Dec, 2020
(5 years ago) | |
| US6965027 | PF PRISM CV | Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate |
Mar, 2023
(2 years ago) | |
| USRE41783 | PF PRISM CV | Pyrrolo[2,3-D]pyrimidine compounds |
Dec, 2025
(a month ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7842699 | PF PRISM CV | Pyrrolo[2,3-D]pyrimidine compounds |
Dec, 2020
(5 years ago) | |
| US6956041 | PF PRISM CV | Pyrrolo[2,3-d]pyrimidine compounds |
Dec, 2020
(5 years ago) | |
| US7301023 | PF PRISM CV | Chiral salt resolution |
May, 2022
(3 years ago) | |
| US6965027 | PF PRISM CV | Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate |
Mar, 2023
(2 years ago) | |
| US7091208 | PF PRISM CV | Pyrrolo[2,3-D]pyrimidine compounds |
Dec, 2020
(5 years ago) | |
| US7265221 | PF PRISM CV | Pyrrolo[2,3-d]pyrimidine compounds |
Dec, 2020
(5 years ago) | |
|
USRE41783 (Pediatric) | PF PRISM CV | Pyrrolo[2,3-D]pyrimidine compounds |
Jun, 2026
(4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-135) | Feb 21, 2017 |
| New Chemical Entity Exclusivity(NCE) | Nov 06, 2017 |
| New Indication(I-761) | Dec 14, 2020 |
| New Indication(I-780) | May 30, 2021 |
| New Product(NP) | Sep 25, 2023 |
| New Patient Population(NPP) | Sep 25, 2023 |
| New Indication(I-879) | Dec 14, 2024 |
| M(M-14) | Feb 21, 2028 |
| Pediatric Exclusivity(PED) | Aug 21, 2028 |
Drugs and Companies using TOFACITINIB CITRATE ingredient
NCE-1 date: 22 August, 2027
Market Authorisation Date: 06 November, 2012
Dosage: TABLET
How can I launch a generic of XELJANZ before it's drug patent expiration?
More Information on Dosage
XELJANZ family patents
2. Xeljanz patent expiration
Treatment: NA
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE41783 | PFIZER | Pyrrolo[2,3-D]pyrimidine compounds |
Dec, 2025
(a month ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
USRE41783 (Pediatric) | PFIZER | Pyrrolo[2,3-D]pyrimidine compounds |
Jun, 2026
(4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-135) | Feb 21, 2017 |
| New Chemical Entity Exclusivity(NCE) | Nov 06, 2017 |
| New Indication(I-761) | Dec 14, 2020 |
| New Indication(I-780) | May 30, 2021 |
| New Product(NP) | Sep 25, 2023 |
| New Patient Population(NPP) | Sep 25, 2023 |
| New Indication(I-879) | Dec 14, 2024 |
| M(M-14) | Feb 21, 2028 |
| Pediatric Exclusivity(PED) | Aug 21, 2028 |
Drugs and Companies using TOFACITINIB CITRATE ingredient
Market Authorisation Date: 25 September, 2020
Dosage: SOLUTION
How can I launch a generic of XELJANZ before it's drug patent expiration?
More Information on Dosage
XELJANZ family patents